Nada S Al-Qadheeb1, Yoanna Skrobik, Greg Schumaker, Manuel N Pacheco, Russel J Roberts, Robin R Ruthazer, John W Devlin. 1. 1School of Pharmacy, Northeastern University, Boston, MA.2Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.3Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA.4Department of Psychiatry, Tufts Medical Center, Boston, MA.5Department of Pharmacy, Tufts Medical Center, Boston, MA.6Research Design Center and Biostatistics Research Center, Tufts Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA.
Abstract
OBJECTIVE: To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3). DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Three 10-bed ICUs (two medical and one surgical) at an academic medical center in the United States. PATIENTS: Sixty-eight mechanically ventilated patients with subsyndromal delirium without complicating neurologic conditions, cardiac surgery, or requiring deep sedation. INTERVENTIONS: Patients were randomly assigned to receive IV haloperidol 1 mg or placebo every 6 hours until delirium occurred (Intensive Care Delirium Screening Checklist ≥ 4 with psychiatric confirmation), 10 days of therapy had elapsed, or ICU discharge. MEASUREMENTS AND MAIN RESULTS: Baseline characteristics were similar between the haloperidol (n = 34) and placebo (n = 34) groups. A similar number of patients given haloperidol (12/34 [35%]) and placebo (8/34 [23%]) developed delirium (p = 0.29). Haloperidol use reduced the hours per study day spent agitated (Sedation Agitation Scale ≥ 5) (p = 0.008), but it did not influence the proportion of 12-hour ICU shifts patients spent alive without coma (Sedation Agitation Scale ≤ 2) or delirium (p = 0.36), the time to first delirium occurrence (p = 0.22), nor delirium duration (p = 0.26). Days of mechanical ventilation (p = 0.80), ICU mortality (p = 0.55), and ICU patient disposition (p = 0.22) were similar in the two groups. The proportion of patients who developed corrected QT-interval prolongation (p = 0.16), extrapyramidal symptoms (p = 0.31), excessive sedation (p = 0.31), or new-onset hypotension (p = 1.0) that resulted in study drug discontinuation was comparable between the two groups. CONCLUSIONS: Low-dose scheduled haloperidol, initiated early in the ICU stay, does not prevent delirium and has little therapeutic advantage in mechanically ventilated, critically ill adults with subsyndromal delirium.
RCT Entities:
OBJECTIVE: To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3). DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Three 10-bed ICUs (two medical and one surgical) at an academic medical center in the United States. PATIENTS: Sixty-eight mechanically ventilated patients with subsyndromal delirium without complicating neurologic conditions, cardiac surgery, or requiring deep sedation. INTERVENTIONS:Patients were randomly assigned to receive IV haloperidol 1 mg or placebo every 6 hours until delirium occurred (Intensive Care Delirium Screening Checklist ≥ 4 with psychiatric confirmation), 10 days of therapy had elapsed, or ICU discharge. MEASUREMENTS AND MAIN RESULTS: Baseline characteristics were similar between the haloperidol (n = 34) and placebo (n = 34) groups. A similar number of patients given haloperidol (12/34 [35%]) and placebo (8/34 [23%]) developed delirium (p = 0.29). Haloperidol use reduced the hours per study day spent agitated (Sedation Agitation Scale ≥ 5) (p = 0.008), but it did not influence the proportion of 12-hour ICU shifts patients spent alive without coma (Sedation Agitation Scale ≤ 2) or delirium (p = 0.36), the time to first delirium occurrence (p = 0.22), nor delirium duration (p = 0.26). Days of mechanical ventilation (p = 0.80), ICU mortality (p = 0.55), and ICU patient disposition (p = 0.22) were similar in the two groups. The proportion of patients who developed corrected QT-interval prolongation (p = 0.16), extrapyramidal symptoms (p = 0.31), excessive sedation (p = 0.31), or new-onset hypotension (p = 1.0) that resulted in study drug discontinuation was comparable between the two groups. CONCLUSIONS: Low-dose scheduled haloperidol, initiated early in the ICU stay, does not prevent delirium and has little therapeutic advantage in mechanically ventilated, critically ill adults with subsyndromal delirium.
Authors: J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs Journal: Intensive Care Med Date: 1996-07 Impact factor: 17.440
Authors: Kees J Kalisvaart; Jos F M de Jonghe; Marja J Bogaards; Ralph Vreeswijk; Toine C G Egberts; Bart J Burger; Piet Eikelenboom; Willem A van Gool Journal: J Am Geriatr Soc Date: 2005-10 Impact factor: 5.562
Authors: E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: W A Knaus; D P Wagner; E A Draper; J E Zimmerman; M Bergner; P G Bastos; C A Sirio; D J Murphy; T Lotring; A Damiano Journal: Chest Date: 1991-12 Impact factor: 9.410
Authors: Michael Klompas; Deverick Anderson; William Trick; Hilary Babcock; Meeta Prasad Kerlin; Lingling Li; Ronda Sinkowitz-Cochran; E Wesley Ely; John Jernigan; Shelley Magill; Rosie Lyles; Caroline O'Neil; Barrett T Kitch; Ellen Arrington; Michele C Balas; Ken Kleinman; Christina Bruce; Julie Lankiewicz; Michael V Murphy; Christopher E Cox; Ebbing Lautenbach; Daniel Sexton; Victoria Fraser; Robert A Weinstein; Richard Platt Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 30.528
Authors: Matthew S Duprey; Nada Al-Qadheeb; Russel Roberts; Yoanna Skrobik; Greg Schumaker; John W Devlin Journal: Intensive Care Med Date: 2016-09-16 Impact factor: 17.440
Authors: Elizabeth Colantuoni; Mounica Koneru; Narjes Akhlaghi; Ximin Li; Mohamed D Hashem; Victor D Dinglas; Karin J Neufeld; Michael O Harhay; Dale M Needham Journal: Trials Date: 2021-05-20 Impact factor: 2.279
Authors: Mark van den Boogaard; Arjen J C Slooter; Roger J M Brüggemann; Lisette Schoonhoven; Albertus Beishuizen; J Wytze Vermeijden; Danie Pretorius; Jan de Koning; Koen S Simons; Paul J W Dennesen; Peter H J Van der Voort; Saskia Houterman; J G van der Hoeven; Peter Pickkers; Anna Besselink; Lieuwe S Hofstra; Peter E Spronk; Walter van den Bergh; Dirk W Donker; Malaika Fuchs; Attila Karakus; M Koeman; Mirella van Duijnhoven; Gerjon Hannink Journal: JAMA Date: 2018-02-20 Impact factor: 56.272
Authors: Behrooz Farzanegan; Takwa H M Elkhatib; Alaa E Elgazzar; Keivan G Moghaddam; Mohammad Torkaman; Mohammadreza Zarkesh; Reza Goharani; Farshid R Bashar; Mohammadreza Hajiesmaeili; Seyedpouzhia Shojaei; Seyed J Madani; Amir Vahedian-Azimi; Sevak Hatamian; Seyed M M Mosavinasab; Masoum Khoshfetrat; Ali K Khatir; Andrew C Miller Journal: J Relig Health Date: 2021-04
Authors: Melanie Smith Condeni; Alyson T Basting; Patrick G Costello; Ashley DePriest; Evert A Eriksson; Heather Evans; Kristie Hertel; Andre L Holder; Alyssa N Kester; Kinsey R Kowalski; Carolyn Magee Bell; Barbara McLean; Michael Reichert; Melissa Santibañez; Patrick M Wieruszewski; Andrea Sikora Newsome Journal: J Crit Care Date: 2020-12-27 Impact factor: 3.425